Evidence mapPaperPMID 38568428Full record

ArticleEJNMMI physics2024

Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT.

Dagmar Grob, Bastiaan M Privé, Constantijn H J Muselaers, Niven Mehra, James Nagarajah, Mark W Konijnenberg, Steffie M B Peters

Open access · goldAbstract read
In one paragraph

Article in EJNMMI physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dagmar GrobDepartment of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Bastiaan M PrivéDepartment of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Constantijn H J MuselaersDepartment of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Niven MehraDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
James NagarajahDepartment of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Mark W KonijnenbergDepartment of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Steffie M B PetersDepartment of Medical Imaging, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. steffie.peters@radboudumc.nl.ORCID http://orcid.org/0000-0002-0752-7134
Radboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBone marrow toxicity in advanced prostate cancer patients who receive [

methodsEight mHSPC patients underwent two cycles (3 and 6 GBq) of [

resultsMean bone marrow absorbed dose was significantly different (p < 0.01) for the imaging based method (25.4 ± 8.7 mGy/GBq) and the blood based method (17.2 ± 3.4 mGy/GBq), with an increasing absorbed dose ratio between both methods over time. Bland Altman analysis of both simplification steps showed that differences in absorbed dose were all within the 95% limits of agreement.

conclusionThis study showed that bone marrow absorbed dose after [

Indexed as

177-Lu-PSMAAbsorbed doseBone marrow dosimetryRadionuclide therapy

Identifiers

PMID38568428
PMCPMC10991600
OpenAlexW4393902414

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.